5 things to know about the cost of insulin

REDIRECT 8040

https://priceschool.usc.edu/news/5-things-to-know-about-the-cost-of-insulin/
Story Headline and Deck – USC News *
5 things to know about the cost of insulin
Body Copy *
Just a few weeks after Elon Musk completed his chaotic buyout of Twitter, a phony account posing as pharmaceutical company Eli Lilly – with the Twitter handle @EliLillyandCo, a “verified” blue checkmark and the company logo – tweeted: “We are excited to announce insulin is free now.”
The tweet went viral, as did the outrage directed at the company over the price of insulin – which is, of course, not free.
More than 37 million Americans have diabetes – one in ten people. Approximately 9.3 million Americans take insulin to manage their condition. It’s a lifesaver for millions of people. And yet, the drug’s list price more than doubled between 2012 and 2019.
To understand how we got here, we turned to USC Price School professors and fellows with the USC Schaeffer Center Neeraj Sood and Karen Van Nuys, who have spent years untangling the cost of insulin. They shared five takeaways from their research (also coauthored by Rocio Ribero and Martha Ryan) published last year in JAMA Health Forum.

1. Insulin list prices have been increasing, but that’s not what most patients pay.
Van Nuys: The list price of a drug is like the sticker price on a car. It’s not necessarily what you pay. Patients with health insurance typically pay a copay or a percentage, rather than the full list price, for insulin. Other entities in the supply chain, like pharmacy benefit managers or health plans, also don’t pay the full price because manufacturers give them all sorts of concessions, rebates and discounts. As a result, list price is not a good measure of what we are actually spending on insulin.
Sood: But that doesn’t mean patients are unharmed by this. In fact, our research shows that higher list prices do harm patients, either through higher coinsurance or through higher net costs and rising premiums. Some patients try to stretch their supplies of insulin, and some have died.

2. What manufacturers take home has been decreasing.
Van Nuys: What insulin manufacturers were paid declined precipitously during the time period (2014-2018) that we analyzed. We found that in 2014 manufacturers were taking home 70% of what is spent on insulin; just four years later they received 47%.
What that means is that somebody has been successful in negotiating concessions from manufacturers, and that those concessions have been increasing.

3. What is paid for insulin from all sources has been remarkably stable over recent years.
Van Nuys: Everyone thinks that insulin is getting more expensive over time. That’s because what’s in the news is the list price – which is publicly available. There are other measures that better reflect what is actually being paid for insulin, but these are hidden and can only be sort of teased out by triangulating from multiple disparate sources, which is basically how we did our paper. That information hasn’t been as available, for example, for Sen. Bernie Sanders and other policymakers concerned about the price of insulin.
Sood: The fact that total expenditures on insulin, that is, the total amount paid to manufacturers and supply chain participants, have in fact been so stable means that those concessions have not been used to lower what we pay for insulin; they’ve been going someplace else. It’s not going to manufacturers. It’s not going to patients. Somebody else is getting that money and our research suggests that it’s these middlemen: wholesalers, pharmacies and pharmacy benefit managers (PBMs).
4. What middlemen have been taking home has been increasing.
Sood: The share of insulin expenditures going to middlemen increased markedly during the period we studied. In 2014, these intermediaries accounted for 30% of expenditures. By 2018 their share had increased to 53%.
I was recently asked by a reporter for the Wall Street Journal: Why doesn’t Bernie Sanders understand this point? I think the answer is, this is really complicated.
Van Nuys: This is not easy stuff. It took us two-and-a-half years to write our paper because everything about insulin expenditures is so buried.
To put it another way, all the concessions that manufacturers have been giving are getting sucked up by the supply chain, rather than being passed through to patients. If the supply chain players were content to earn what they were earning in 2014, we would see lower total insulin expenditures. But instead the supply chain has acted like a sponge, soaking up the concessions they have been wringing out of manufacturers and keeping them for themselves.
5. By 2018, middlemen were pocketing more than half of what we spend on insulin.
Sood: Patients and their advocates should ask why it is that the people who distribute insulin, like PBMs and pharmacies, get more than half of the money spent by consumers, and why they should be earning more over time. Since 2018, there has been a string of vertical mergers where PBMs have merged with large insurers, which has further consolidated their market power.
Van Nuys: The bottom line is policymakers who want to control insulin costs should consider entities throughout the insulin distribution system. Policymakers and the public alike have been focused on drug manufacturers – look no further than the anger directed at Eli Lilly, and at the drug-pricing language in the recent Inflation Reduction Act – but we believe a more effective approach is to target what is going to the intermediaries in the drug distribution system. One positive development is that this past June, the Federal Trade Commission opened an investigation into the six largest PBMs. It’s long overdue.
For more research on drug pricing, visit the USC Schaeffer Center.

The post 5 things to know about the cost of insulin appeared first on USC News.

Unlocking the potential of monoclonal antibodies

An experimental Alzheimer’s drug, hailed as a breakthrough, slowed cognition decline in people with early-stage disease, according to a new study in the New England Journal of Medicine. The drug, lecanemab, is a monoclonal antibody — or mAb for short — designed to clear amyloid plaques in the brain that many think are a root cause of Alzheimer’s disease.

“This is the first time we’ve been able to prove that we can slow the progression of Alzheimer’s,” said Paul Aisen, director of the Alzheimer’s Therapeutic Research Institute at the Keck School of Medicine of USC and a co-author on the study. “It’s now clear that removing amyloid can slow disease progression.”

Monoclonal antibodies are an increasingly important tool in our arsenal to fight disease. FDA-approved monoclonal antibodies treat COVID-19, certain types of cancer and even asthma. When combined with radioactive particles, mAbs can home in on prostate cancer cells to show where the disease has spread.

But what are monoclonal antibodies exactly and how do they work? To learn more, USC News sat down with Aisen and Paula Cannon, a Distinguished Professor in the department of molecular microbiology and immunology at the Keck School.

Dr. Cannon, can you begin by explaining how we make our own antibodies?

CANNON: Antibodies are one of the many weapons our immune system has, made by a type of white blood cell we have whizzing around in our body called B cells. The cool thing about antibodies is they are these little Y-shaped molecules, and the tips of the Y in every antibody have a slightly different, unique shape.

Our bodies make an estimated 50 trillion different antibodies, and all these different shapes are displayed on their own host B cell. When you get infected by a virus or a bacterium, the very rare antibody that happens to have the right shape on the tips of its Y binds to the virus when it touches it.

The antibody initially sits on the outside of the B cell, and this contact with the invader triggers the B cell. It starts to grow and divide and make lots and lots of B cells and they’re all now spewing out these specific antibodies into the blood, to go hunt for more of their target.

Monoclonal antibodies are laboratory-made versions of that, correct?

CANNON: That’s right. When we talk about monoclonal antibodies, it’s just an unnecessarily long-winded way of saying an antibody with a single or “mono” shape. You’re giving people antibodies they haven’t already made, doing an end run around nature. COVID is a great example. Antibodies against COVID bind to the virus’s spike protein, preventing it from infecting healthy cells.

Monoclonal antibodies — the manmade version — are good for people who are older, sicker, immune deficient and aren’t having a good response to the vaccine or making their own antibodies.

In addition to blocking or neutralizing a virus, antibodies — both natural and lab-made — work in other ways, right?

CANNON: Another thing that antibodies can do is stick onto the surface of, say, a cancer cell. And remember, antibodies are Y-shaped. The tips dock onto the cancer cell but the tail also does some work — it can beckon over other components of the immune system to engulf or kill those cancer cells.

Dr. Aisen, what is the mechanism behind monoclonal antibodies for Alzheimer’s? How do those work?

AISEN: There are many different antibodies being developed for Alzheimer’s. The common feature of antibodies that remove amyloid plaques is they bind tightly to amyloid plaques in the brain in a way that enables microglial cells — which are the brain’s waste collectors — to chew up plaques.

Normally, plaques are resistant to microglial clearance, but the binding of the antibodies facilitates microglial binding and digestion of plaques. Evidence suggests the amyloid fragments are leaving through the microvasculature, tiny blood vessels in the brain, in a process that can damage vessel walls. That’s the reason, we think, that these antibody treatments can cause adverse effects such as tiny hemorrhages and areas of brain swelling.

What’s the next step for mAbs as an Alzheimer’s treatment?

AISEN: We think the benefit will be greater if we treat earlier. Amyloid accumulates for 10 to 15 years before the onset of symptoms. We should remove the amyloid before symptoms start, that is, while brain function is still pretty normal.

In Alzheimer’s, different forms of amyloid accumulate in the brain, including monomers, small aggregates called oligomers, protofibrils, fibrils and plaques. Some people believe it’s the smaller forms of amyloid that do more damage than the plaques themselves. That’s still a matter of debate.

There is one antibody that only binds to monomers, which are single, tiny pieces of amyloid. This antibody is called solanezumab. Since it has a limited effect on plaques, it does not cause microhemorrhages or brain swelling. And our hope is that at an early stage this will be effective.

 

The post Unlocking the potential of monoclonal antibodies appeared first on USC News.

National survey sheds light on dimensions of teen mental health concerns

REDIRECT https://healthpolicy.usc.edu/evidence-base/national-survey-findings-shed-light-on-dimensions-of-teen-mental-health-concerns/

National Survey Findings Shed Light on Dimensions of Teen Mental Health Concerns
By Amie Rapaport and Daniel Silver
November 11, 2022
Press contact:Stephanie Hedt(213) 821-4555
Posted in EVIDENCE BASE

IMAGE/SHUTTERSTOCK
Story after tragic story has emerged about the havoc that the COVID-19 pandemic has inflicted on the mental health of children and teens. From losing family members to disease, to school closures and continued school disruptions, to limited peer interactions and fractured social lives, the possible factors influencing worsening mental health are numerous. Though experts have been careful to emphasize that the COVID pandemic exacerbated an already existing mental health crisis, a consistent trend both inside and outside the United States is that girls seem to have been disproportionately affected compared to boys.

In April 2022, researchers at USC’s Center for Economic and Social Research asked a nationally representative sample of households to complete a survey (the Strengths and Difficulties Questionnaire [SDQ]) about the mental health of a child in their home (we selected one of their children at random if they had more than one) as part of the Understanding America Study (UAS). This psychometrically validated instrument is one of the most commonly used tools for screening mental health in children and adolescents. Comparing results to those from the same battery of questions posed to a different, but also nationally representative, sample in 2013 (He et. al) reveals interesting and important patterns about the changes underlying worsening mental health over the last decade.[1]

Our findings document worsening mental health since 2013 among both boys and girls, with results shedding light on areas of particular concern and a troubling pattern among girls. With continued tracking over time, we hope to help inform interventions and outreach, particularly in schools, that can help mitigate the ongoing mental health crisis facing our nation’s youth.

Small decline in overall mental health measure masks important changes

Perhaps surprisingly, the overall mental health “difficulties” score (higher scores represent more negative experiences) in 2022 was only a bit higher than it was in 2013 (8.2 compared to 7.9). However, this subtle change at the overall level masks opposing patterns in particular areas, or domains, of mental health (Figure 1). First, there was a statistically significant increase in the Hyperactivity domain (e.g., restless, overactive, easily distracted, fidgeting/squirming), accompanied by a statistically significant decrease in the Conduct Problems domain (e.g., often loses temper, fights with other youth, lies or cheats). In other words, when reporting on the mental health of a child, parents in 2022 reported more restlessness, distraction, fidgeting-type behaviors than a group of parents reported on their children in 2013; but they also reported fewer fights, lying, cheating and losing temper-like behaviors.

FIGURE 1. HIGHER (WORSE) SCORES IN HYPERACTIVITY; LOWER (BETTER) SCORES IN CONDUCT PROBLEMS
*Significant difference between the average score in 2013 and the average score in 2022 (p<.05)

We also observed higher scores (i.e., more difficulties) in the Emotional Symptoms domain and the Peer Relationships domain, though these changes were smaller and not statistically significant.

More negative scores for girls than for boys

When looking at results by gender of the child, we see similar drops in the Conduct Problems domain compared to the 2013 snapshot, and similar increases in the Hyperactivity domain for both boys and girls (Figure 2). Notably, though, the magnitude of change for girls was always worse than for boys – in all domains that compose the scale. Difficulty scores were larger for girls than boys in the Emotional Symptoms, Hyperactivity, and Peer Relationships domains, and the relative positive lower score in the Conduct Problems domain was smaller for girls. Further exacerbating concerns about girls’ mental health, the relative protective increase in the Prosocial Behaviors domain (the “Strengths” of the SDQ) was smaller for girls than for boys. Though these patterns were not always statistically significant, they align with recent findings that girls’ mental health is in a heightened state of crisis.

FIGURE 2. WORSENING MENTAL HEALTH EXPERIENCES FOR GIRLS IN EVERY DOMAIN (MORE DIFFICULTIES, FEWER STRENGTHS)
Girls suffering more than boys in 2022, as evidenced by anxiety and depression items

As noted, scores for girls in the difficulty domains were higher (worse) in 2022 than in 2013. When looking only at 2022 data (Table 1), girls’ Emotional Symptoms score was significantly higher (worse) than boys’. This domain includes items such as “often seems worried”, “has many fears”, and “often unhappy, depressed or tearful”. In 2022 girls scored almost one full point higher (worse) on this domain scale compared to boys. Boys are struggling more than girls in the area of Hyperactivity (i.e., Hyperactivity scores were higher (worse) for boys), but the difference between boys and girls on that domain is almost half what it is for the Emotional Symptoms domain. Importantly, girls score significantly higher (better) than boys on the potentially protective strength domain of prosocial behaviors (7.83 for girls compared to 7.22 for boys), though as shown above, this domain score increased more (improved more) for boys than it did for girls since 2013.

Table 1. Differences in domain scores between girls and boys in 2022

Boys Girls Difference
(Sum) Total Difficulties 7.92 8.36 .44
Emotional Symptoms 1.53 2.45 .92*
Conduct Problems 0.99 0.92 -.07
Hyperactivity 3.38 2.97 -.41
Peer Relationships 2.03 1.99 -.04
(+) Prosocial Behaviors 7.22 7.83 .61*
*Significant difference between boys and girls in 2022, p<.05

Results can inform targeting of mental health strategies and resources

Our lens on youth mental health post-pandemic can inform strategies for allocating large-scale investments in youth mental health services in schools. There is a clear need to consider the experiences of girls, whose parents are reporting significantly more reports of depression and anxiety today for their daughters compared to 2013. These results resonate with the terrifying statistics frequently cited relating to the increase in suicide attempts and mental health-related emergency hospital visits among girls. Not only have reports of girls’ symptoms increased in every negative way, the one positive decrease observed (in the Conduct Problems domain) was smaller for girls than it was for boys. We hope these results can be used by mental health experts, school counselors, parents, and others who can learn from these changing patterns, informing interventions and preventative measures.

We plan to re-administer the Strengths and Difficulties Questionnaire periodically over the next two years to the same sample of households, about the same children, allowing us to build within-person measures of mental health and behavior difficulties as they evolve over time, as well as exploring the relationship between differing school-based experiences during the COVID recovery period and related changes reflected in the SDQ over time. We believe these data will contribute productively to discussions of the evolving mental health of students in the post-reopening K-12 school system. It is essential to elevate discussion of the effects of the pandemic on children’s and teens’ mental health to support strong, data-driven policies that have the potential to allocate mental health resources where they are most needed.

[1] We limited our 2022 sample to only parent respondents of children between the ages of 13-18 to maximize similarity to the 2013 sample. The overall 2022 sample is based on a probability-based survey method and is nationally representative. The subgroup of children aged 13-18 is compositionally similar by race/ethnicity, household income, and household education level to the overall nationally representative sample, and matches the age range of the 2013 group.

The post National survey sheds light on dimensions of teen mental health concerns appeared first on USC News.

Discovery involving sodium could lead to safer painkillers such as fentanyl

One of the most abundant elements on Earth — sodium — may hold the key for scientists to develop opioids or other drugs with far fewer side effects.

In a study published Wednesday by Nature, scientists from USC, Washington University in St. Louis and Stanford University demonstrated that by chemically linking fentanyl to the sodium pockets that exist within nerve cell receptors, they could block the drug’s harmful side effects and still reduce pain.

Further study is needed, but the results hold promise — not just for drug development but also for addressing the nation’s crisis of addiction and overdose. Nearly 70,000 Americans died in 2020 of an opioid overdose — most of them from the synthetic opioid fentanyl, according to the National Institute on Drug Abuse. In the 1990s, the Food and Drug Administration approved the use of fentanyl to ease severe pain in cancer patients but it has since made its way into the streets, worsening the national crisis of opioid abuse.

“In its current form, fentanyl is like a weapon of mass destruction,” said Vsevolod Katritch, a computational scientist at the Bridge Institute at the USC Michelson Center for Convergent Bioscience and a corresponding author of the study. “Our new collaborative work suggests that we could redesign the drug in such a way that we convert this frequent overdose killer to a much more benign but still effective analgesic.”

Drugs of all kinds are designed to target certain receptors on nerve cells known as GPCRs (G protein-coupled receptors), which act as signal transmitters. These receptors are like switches that mediate a drug’s intended effect on the brain and body, but also the unintended side effects. In the case of fentanyl, the most potent painkiller of all opioids, patients may suffer addiction and may die from respiratory arrest.

Research involving the sodium mechanism

Katritch noted that he and his fellow scientists Ray Stevens and Vadim Cherezov at the Bridge Institute and the USC Dornsife College of Letters, Arts and Sciences have been looking at the potential of the sodium mechanism since they first identified it within adenosine and opioid receptors about a decade ago.

Katritch and his collaborators said that although further study is needed to prove that their less harmful version of fentanyl will work in humans, the results have opened a new door for scientists to potentially improve the safety of painkillers.

“We are desperately looking for ways to maintain the analgesic effects of opioids, while avoiding dangerous side effects such as addiction and respiratory distress that too often lead to death,” said corresponding author Susruta Majumdar of Washington University in St. Louis. “Our research is still in its early stages, but we’re excited about its potential for leading to safer pain-relieving drugs.”

Beyond opioid receptors, noted Katritch, this work opens a new molecular design concept for dozens of other GPCRs where such functional conversion in existing drugs would be desirable.


Other study co-authors were 2012 Nobel laureate Brian Kobilka at Stanford Medicine, Georgios Skiniotis of Stanford University and Jay P. McLaughlin at the University of Florida.

The study was supported by grants from the National Institute on Drug Abuse and the National Cancer Institute of the National Institutes of Health. Grant numbers include R33 DA045884, R01 DA042888, R01 DA007242, R37 DA036246, R33DA 038858, P01 DA035764, R21 DA048650, R00 DA038725 and P30 CA008748. Additional funding provided by an American Heart Association Postdoctoral Fellowship, the Mathers Foundation, the Brain & Behavior Research Foundation and other funders.

The post Discovery involving sodium could lead to safer painkillers such as fentanyl appeared first on USC News.

Keck Medicine of USC Looks East

Picture this: A patient arrives at a local hospital’s emergency room short of breath. Emergency room physicians run scans that reveal a bilateral pulmonary embolism. The community hospital doesn’t have a pulmonary embolism response team but partners with an academic hospital that has one–so the two hospitals coordinate the patient’s transfer.

Less than two hours later, doctors from the academic medical center–specializing in interventional radiology, pulmonology and pulmonology hypertension–successfully remove the embolism. The patient, now out of danger, isn’t expected to have lingering problems.

This orchestration of care is just one of the many ways Keck Medicine of USC hopes the San Gabriel Valley community will benefit from its recently announced partnership with Methodist Hospital of Southern California in Arcadia, now known as USC Arcadia Hospital.

The new collaboration will expand the university’s and its medical enterprise’s footprint as a leading provider of health care in Southern California and beyond. In 2024, a new, state-of-the-art medical office building in Pasadena for various Keck Medicine practices will open, enabling partnerships that send Keck Medicine physicians as far as Visalia and Las Vegas.

“Having specialized university physicians readily available to support community physicians through doctor-to-doctor communication and collaboration provides timely information that may be critical to informing a patient’s treatment plan,” says Keck Medicine of USC CEO Rod Hanners. Through this affiliation, San Gabriel Valley patients can access the complex care they need from Keck Medicine’s clinicians, while continuing their ongoing care with their community physicians.

With the strength of education, research and clinical care represented by the university’s five health-related schools (which represent 55% of the university’s total research, 70% of total full-time faculty and 54% of fulltime staff), Keck Medicine is well-poised to provide this level of care. Through team-based collaboration, Keck Medicine utilizes the diverse expertise of the university’s many health disciplines.

Expanding Keck Medicine’s clinical enterprise is also vital to fulfilling USC President Carol L. Folt’s vision for USC health sciences.

In her State of the University address from the Health Sciences Campus last April, Folt said her goals included a commitment to growing the university’s health sciences for maximum impact. She also supports expanding the schools’ research, clinical practice, community outreach and student aid through the USC Campaign for Health and cross-school collaboration that “addresses some of the greatest issues and opportunities of our time.”

Interdisciplinary Collaboration for Team-Based Care

Steven Shapiro, USC’s senior vice president for health affairs who oversees Keck Medicine of USC and the Keck School of Medicine of USC, hopes the USC Arcadia Hospital affiliation moves the needle on all three goals.

Shapiro, a physician-scientist who was hired last year to promote greater collaboration across the university, aims to position USC as an important clinical leader in the increasingly competitive Los Angeles health care market.

One priority of the collaboration is building a care model that combines disparate disciplines to provide comprehensive care.

Instead of visiting multiple health centers for care, patients can work with one integrated team who understands their health background, from primary care to more complex specialty services.

The nation’s aging population highlights why this team-based care is needed.

“Most of the health problems we see in our country are related to aging,” Shapiro says. Each of USC’s health science schools contributes to an effective care team, including social workers who keep in touch with patients, pharmacists who deliver the most effective medications and specialists in gerontology who understand aging patients.

He also sees community partnerships, such as the USC Arcadia Hospital acquisition, as an opportunity to move away from the U.S. health care system’s episodic model of treatment. USC’s medical enterprise will embrace a more “continuous care model,” where cross-disciplinary partnerships combine with community understanding and specialty services to deliver the best patient care possible.

“All these different groups coming together will allow us to provide team-based care in the clinical setting,” Shapiro says. “This kind of collaboration gives us a diversity of opinions and ideas to approach the research problems we have as well. We believe taking advantage of all the great schools we have at USC is a great start.”

Preserving Local Values

The collaboration comes at a critical time: Across the nation, individual corporations and academic health centers are consolidating health care and controlling health care markets. With less competition in those regions, larger entities are free to set higher prices that are often passed down to patients in the form of more expensive hospital bills and insurance premiums.

While Southern California has a more diverse health care market than much of the country, the region is starting to the diverse San Gabriel Valley in a sustainable way while expanding the reach of its clinical enterprise,” Robinson says. As a result, local stand-alone hospitals struggle to thrive and offer quality, affordable care to their patients.

To ensure that Keck Medicine’s newest collaboration preserves USC Arcadia Hospital’s connection to its community and its patients while delivering a high level of care, both sides of the partnership must engage in a period of learning and understanding, says physician Jehni Robinson, president of USC Care Medical Group, chair of the department of family medicine and associate dean for primary care at the Keck School.

Likewise, Robinson describes cultural humility as an ongoing and “critically important journey” that involves working toward faculty and staff reflecting the communities they’ll be serving as Keck Medicine’s medical enterprise continues to expand.

Robinson says that Keck Medicine has approached community partnerships in the past with an eye for what each region needs and a recognition of the high-quality care these hospitals already provide.

By joining Keck Medicine, USC Arcadia Hospital will be able to preserve its 100-plus-year history of providing primary health care.

By joining Keck Medicine, USC Arcadia Hospital will be able to preserve its 100-plus-year history of providing primary health care. The San Gabriel Valley community will also benefit from the addition of Keck Medicine’s expertise in treating more complex cases that require highly specialized skills, technology and resources. The majority of care will still occur at USC Arcadia Hospital. Still, highly complex cases that require specialized academic medicine (such as organ transplants and robotic surgery) can be seamlessly handled at Keck Medical Center of USC on the USC Health Sciences Campus.

“I think it’s a real opportunity for a win-win scenario where Keck Medicine can provide highly specialized care to the diverse San Gabriel Valley in a sustainable way while expanding the reach of its clinical enterprise,” Robinson says.

Over the coming years, Keck Medicine will invest in USC Arcadia Hospital’s physician recruitment and professional development, equipment, infrastructure and services in neurosciences, cardiac care and oncology.

Additionally, the health system will develop academic and training relationships for USC residents and fellows at USC Arcadia Hospital.

A History of Successful Partnerships

With this affiliation, Keck Medicine now has two community hospitals in the northeast area of Los Angeles. USC Arcadia Hospital joins USC Verdugo Hills Hospital, which has served La Canada Flintridge, Glendale and the greater foothills community for more than 40 years.

In 2009, Keck Medicine began a tradition of successful collaborations with regional hospitals and health enterprises, improving access to academic medicine in local communities.

Then-USC President Steven B. Sample hailed the purchase of the USC University Hospital (now Keck Hospital of USC) and USC Norris Cancer Hospital to establish what was then known as the USC Academic Medical Center as one that would “create deeper connections among disciplines on both campuses in order to enhance research, teaching and patient care.”

The medical system–which changed its name to Keck Medicine of USC in 2011–further expanded in 2013 with the acquisition of USC Verdugo Hills Hospital. The Keck Medicine system bolstered its community-based services through that hospital’s 24-hour emergency department, primary stroke center, maternity/labor and delivery, cardiac rehabilitation, and imaging and diagnostic services.

Throughout this time, Keck Medicine also established stand-alone outpatient clinics across Southern California and partnerships with other community hospitals to help bring specialized care to areas without. Affiliated physicians provide care in more than 80 outpatient locations in Los Angeles, Orange, Kern, Tulare and Ventura counties.

Keck Medicine leaders say this growth is essential to maintaining USC’s position as a leading academic health center.

“We’re an outstanding health system, but we’re relatively small for an academic health system,” Shapiro says. “The larger we are, the more resources we have to provide the best care possible for our patients in state-of-the-art facilities and to support the academic mission that helps us do the science and translate it back to our communities.”

Hanners agrees, describing the relationship between the university and its growing medical enterprise and community partnerships as a “virtuous cycle.” “This growth creates the margins that allow the health system to support the academic mission, which then spurs new discoveries that help us provide better services at the bedside for our patients,” he says.

With this newest partnership, Hanners hopes the medical enterprise can continue to learn meaningful and intentional ways to connect with diverse communities and the dedicated hospital staff that serve them.

“We’re very focused on meeting with the medical staff out there in the community and reassuring them that we’re here to fill gaps, raise the level of care and provide services that they otherwise are not getting–not compete with them and take away their livelihoods,” Hanners says.

This is something that we are very proud of and, we believe, differentiates our approach to working with community providers.

Rod Hanners

Fueled by lessons from the Verdugo Hills partnership years before, Keck Medicine’s physician leaders held town halls early in the acquisition process to engage with Arcadia hospital leadership to alleviate concerns, answer questions and build trust “doctor-to-doctor.”

“This is something that we are very proud of and, we believe, differentiates our approach to working with community providers,” Hanners says. “It is a team concept where we want to be an asset to the community providers in helping improve the care for their patients.”

All in all, Keck Medicine’s leaders are excited by the university’s expansion into the unique eastern communities of the San Gabriel Valley.

“I think we are limitless in terms of the opportunities that we have to make a difference for individual patients, families and communities,” Robinson says. “We get to take the important work we’re doing and open up access to it for the diverse communities we serve. I’m very excited to be part of Keck Medicine of USC at this critically important moment.”

The post Keck Medicine of USC Looks East appeared first on USC News.

Keck Medicine of USC Looks East

Health

Keck Medicine of USC Looks East

With the recent USC Arcadia Hospital affiliation, Keck Medicine of USC continues its tradition of innovation, growth and community partnership.

November 28, 2022

Chinyere Cindy Amobi

Picture this: A patient arrives at a local hospital’s emergency room short of breath. Emergency room physicians run scans that reveal a bilateral pulmonary embolism. The community hospital doesn’t have a pulmonary embolism response team but partners with an academic hospital that has one—so the two hospitals coordinate the patient’s transfer.

Less than two hours later, doctors from the academic medical center—specializing in interventional radiology, pulmonology and pulmonology hypertension—successfully remove the embolism. The patient, now out of danger, isn’t expected to have lingering problems.

This orchestration of care is just one of the many ways Keck Medicine of USC hopes the San Gabriel Valley community will benefit from its recently announced partnership with Methodist Hospital of Southern California in Arcadia, now known as USC Arcadia Hospital.

The new collaboration will expand the university’s and its medical enterprise’s footprint as a leading provider of health care in Southern California and beyond. In 2024, a new, state-of-the-art medical office building in Pasadena for various Keck Medicine practices will open, enabling partnerships that send Keck Medicine physicians as far as Visalia and Las Vegas.

“Having specialized university physicians readily available to support community physicians through doctor-to-doctor communication and collaboration provides timely information that may be critical to informing a patient’s treatment plan,” says Keck Medicine of USC CEO Rod Hanners. Through this affiliation, San Gabriel Valley patients can access the complex care they need from Keck Medicine’s clinicians, while continuing their ongoing care with their community physicians.

With the strength of education, research and clinical care represented by the university’s five health-related schools (which represent 55% of the university’s total research, 70% of total full-time faculty and 54% of fulltime staff), Keck Medicine is well-poised to provide this level of care. Through team-based collaboration, Keck Medicine utilizes the diverse expertise of the university’s many health disciplines.

Expanding Keck Medicine’s clinical enterprise is also vital to fulfilling USC President Carol L. Folt’s vision for USC health sciences.

In her State of the University address from the Health Sciences Campus last April, Folt said her goals included a commitment to growing the university’s health sciences for maximum impact. She also supports expanding the schools’ research, clinical practice, community outreach and student aid through the USC Campaign for Health and cross-school collaboration that “addresses some of the greatest issues and opportunities of our time.”

Interdisciplinary Collaboration for Team-Based Care

Exterior shot of USC Arcadia Hospital
USC Arcadia Hospital began operating in 1903 as Methodist Hospital of Southern California; it became affiliated with the Keck Medicine health system on July 1, 2022. (Photo/Ricardo Carrasco III)

Steven Shapiro, USC’s senior vice president for health affairs who oversees Keck Medicine of USC and the Keck School of Medicine of USC, hopes the USC Arcadia Hospital affiliation moves the needle on all three goals.

Shapiro, a physician-scientist who was hired last year to promote greater collaboration across the university, aims to position USC as an important clinical leader in the increasingly competitive Los Angeles health care market.

One priority of the collaboration is building a care model that combines disparate disciplines to provide comprehensive care.

Instead of visiting multiple health centers for care, patients can work with one integrated team who understands their health background, from primary care to more complex specialty services.

The nation’s aging population highlights why this team-based care is needed.

“Most of the health problems we see in our country are related to aging,” Shapiro says. Each of USC’s health science schools contributes to an effective care team, including social workers who keep in touch with patients, pharmacists who deliver the most effective medications and specialists in gerontology who understand aging patients.

He also sees community partnerships, such as the USC Arcadia Hospital acquisition, as an opportunity to move away from the U.S. health care system’s episodic model of treatment. USC’s medical enterprise will embrace a more “continuous care model,” where cross-disciplinary partnerships combine with community understanding and specialty services to deliver the best patient care possible.

“All these different groups coming together will allow us to provide team-based care in the clinical setting,” Shapiro says. “This kind of collaboration gives us a diversity of opinions and ideas to approach the research problems we have as well. We believe taking advantage of all the great schools we have at USC is a great start.”

Preserving Local Values

The collaboration comes at a critical time: Across the nation, individual corporations and academic health centers are consolidating health care and controlling health care markets. With less competition in those regions, larger entities are free to set higher prices that are often passed down to patients in the form of more expensive hospital bills and insurance premiums.

While Southern California has a more diverse health care market than much of the country, the region is starting to the diverse San Gabriel Valley in a sustainable way while expanding the reach of its clinical enterprise,” Robinson says. As a result, local stand-alone hospitals struggle to thrive and offer quality, affordable care to their patients.

To ensure that Keck Medicine’s newest collaboration preserves USC Arcadia Hospital’s connection to its community and its patients while delivering a high level of care, both sides of the partnership must engage in a period of learning and understanding, says physician Jehni Robinson, president of USC Care Medical Group, chair of the department of family medicine and associate dean for primary care at the Keck School.

Likewise, Robinson describes cultural humility as an ongoing and “critically important journey” that involves working toward faculty and staff reflecting the communities they’ll be serving as Keck Medicine’s medical enterprise continues to expand.

Robinson says that Keck Medicine has approached community partnerships in the past with an eye for what each region needs and a recognition of the high-quality care these hospitals already provide.

By joining Keck Medicine, USC Arcadia Hospital will be able to preserve its 100-plus-year history of providing primary health care.

By joining Keck Medicine, USC Arcadia Hospital will be able to preserve its 100-plus-year history of providing primary health care. The San Gabriel Valley community will also benefit from the addition of Keck Medicine’s expertise in treating more complex cases that require highly specialized skills, technology and resources. The majority of care will still occur at USC Arcadia Hospital. Still, highly complex cases that require specialized academic medicine (such as organ transplants and robotic surgery) can be seamlessly handled at Keck Medical Center of USC on the USC Health Sciences Campus.

“I think it’s a real opportunity for a win-win scenario where Keck Medicine can provide highly specialized care to the diverse San Gabriel Valley in a sustainable way while expanding the reach of its clinical enterprise,” Robinson says.

Over the coming years, Keck Medicine will invest in USC Arcadia Hospital’s physician recruitment and professional development, equipment, infrastructure and services in neurosciences, cardiac care and oncology.

Additionally, the health system will develop academic and training relationships for USC residents and fellows at USC Arcadia Hospital.

A History of Successful Partnerships

With this affiliation, Keck Medicine now has two community hospitals in the northeast area of Los Angeles. USC Arcadia Hospital joins USC Verdugo Hills Hospital, which has served La Cañada Flintridge, Glendale and the greater foothills community for more than 40 years.

In 2009, Keck Medicine began a tradition of successful collaborations with regional hospitals and health enterprises, improving access to academic medicine in local communities.

Then-USC President Steven B. Sample hailed the purchase of the USC University Hospital (now Keck Hospital of USC) and USC Norris Cancer Hospital to establish what was then known as the USC Academic Medical Center as one that would “create deeper connections among disciplines on both campuses in order to enhance research, teaching and patient care.”

The medical system—which changed its name to Keck Medicine of USC in 2011—further expanded in 2013 with the acquisition of USC Verdugo Hills Hospital. The Keck Medicine system bolstered its community-based services through that hospital’s 24-hour emergency department, primary stroke center, maternity/labor and delivery, cardiac rehabilitation, and imaging and diagnostic services.

Throughout this time, Keck Medicine also established stand-alone outpatient clinics across Southern California and partnerships with other community hospitals to help bring specialized care to areas without. Affiliated physicians provide care in more than 80 outpatient locations in Los Angeles, Orange, Kern, Tulare and Ventura counties.

Keck Medicine leaders say this growth is essential to maintaining USC’s position as a leading academic health center.

“We’re an outstanding health system, but we’re relatively small for an academic health system,” Shapiro says. “The larger we are, the more resources we have to provide the best care possible for our patients in state-of-the-art facilities and to support the academic mission that helps us do the science and translate it back to our communities.”

Hanners agrees, describing the relationship between the university and its growing medical enterprise and community partnerships as a “virtuous cycle.” “This growth creates the margins that allow the health system to support the academic mission, which then spurs new discoveries that help us provide better services at the bedside for our patients,” he says.

With this newest partnership, Hanners hopes the medical enterprise can continue to learn meaningful and intentional ways to connect with diverse communities and the dedicated hospital staff that serve them.

“We’re very focused on meeting with the medical staff out there in the community and reassuring them that we’re here to fill gaps, raise the level of care and provide services that they otherwise are not getting—not compete with them and take away their livelihoods,” Hanners says.

This is something that we are very proud of and, we believe, differentiates our approach to working with community providers.

Rod Hanners

Fueled by lessons from the Verdugo Hills partnership years before, Keck Medicine’s physician leaders held town halls early in the acquisition process to engage with Arcadia hospital leadership to alleviate concerns, answer questions and build trust “doctor-to-doctor.”

“This is something that we are very proud of and, we believe, differentiates our approach to working with community providers,” Hanners says. “It is a team concept where we want to be an asset to the community providers in helping improve the care for their patients.”

All in all, Keck Medicine’s leaders are excited by the university’s expansion into the unique eastern communities of the San Gabriel Valley.

“I think we are limitless in terms of the opportunities that we have to make a difference for individual patients, families and communities,” Robinson says. “We get to take the important work we’re doing and open up access to it for the diverse communities we serve. I’m very excited to be part of Keck Medicine of USC at this critically important moment.”

The post Keck Medicine of USC Looks East appeared first on USC Today.

Pioneering pharmacy professor learned early to work hard and help others


Editor’s note: Title IX — the landmark legislation that prohibits sex discrimination in educational institutions that receive federal funding — was signed into law on June 23, 1972. In recognition of this anniversary, we’ll be profiling Trojan Title IX trailblazers throughout the academic year.

When Jean Chen Shih interviewed for a faculty position at the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences in 1974, she was told there were 70 other applicants for the job and left campus feeling unsure about her chances. Shih was nearly nine months pregnant, but no one seemed to notice after two days of interviews and a seminar presentation.

Title IX logo

Just days after giving birth to her second son, Shih received a call from a man congratulating her. She replied, “Thank you! It’s a boy!” After some confusion, Shih was surprised to discover she was not speaking with a family well-wisher but with the head of the USC search committee who was calling with an offer to join the faculty.

“He said, ‘I didn’t know you were about to deliver a baby,'” she recalled. “I didn’t know if it was an important issue and didn’t know what they thought about it.”

Shih didn’t ask; she just got to work. During her nearly five-decade career at USC, she has done groundbreaking scientific research and become a world leader in understanding the neurobiological and biochemical mechanisms behind such behaviors as aggression and anxiety. She is also developing cancer drugs with dual therapy and diagnosis functions.

She is a University Professor and holds the endowed Boyd P. and Elsie D. Welin Professor of Pharmaceutical Sciences chair. Her areas of expertise include brain development, autism spectrum disorder and repurposing antidepressants for brain cancer and prostate cancer.

Shih’s many honors and accomplishments include two prestigious MERIT (Method to Extend Research in Time) Awards from the National Institutes of Health. Fewer than 1% of researchers who apply for federal funding are chosen to receive a MERIT Award, which provides five years of grant support with the option of an additional five years. She is the only faculty member to hold this honor in USC history. She is also the founding director of USC-Taiwan Center for Translational Research and past president of the Society of Chinese Bioscientists in America, a leader in global interdisciplinary and translational research.

Title IX trailblazer: Working twice as hard

Title IX had been signed into law just two years before Shih’s hiring at USC. The landmark law prohibits sex-based discrimination in any school or other educational program receiving funding from the federal government.

“Most women like me didn’t know what our rights were,” Shih said of her early days at USC. “When anything would happen to us that wasn’t fair, we just thought, ‘That’s the way it is.'”

The discrimination wasn’t obvious, but it was there.

“In 1974, there were fewer female faculty members, and our slogan was always, ‘A woman has to work twice as hard to get credit,'” Shih said.

Title IX also couldn’t make it easier for Shih to juggle her responsibilities at work and at home.

“Sometimes a faculty meeting would go past 5 p.m., and I’d have to pick up my son from school,” she said. “But at that time, I was afraid to say, ‘I cannot stay.’ I would get to the school and there would be my son standing at the football field by himself waiting for his mother to pick him up. I’d feel terrible.”

She pointed out that faculty meetings began to finish much earlier once male faculty members became involved in picking up their kids as well.

Although Shih has seen changes and improvements, she believes Title IX is as important now as it was 50 years ago.

“Now we have more female students, and I think this law has really helped people at all levels to see the importance of equal rights — especially in education,” Shih said. “It’s very important that more and more people are aware of this law. Then, I think the improvement will be expanded exponentially.”

A mother’s example to a Title IX trailblazer

Born in China, Shih moved with her family to Taiwan when she was 8 years old. She lived there until after graduating as valedictorian with a bachelor’s degree in biochemistry from National Taiwan University.

Shih said “education was always everything” because of the influence of her “trailblazer” mother.

“I was brought up to always do my best in everything I do and always try to help others,” Shih said. “I’ve known many Nobel Prize winners, but she is the person I admire the most.”

It never occurred to Shih, the second of three daughters, that she wasn’t as smart as the men in her classes. She had the confidence and the drive to leave Taiwan and earn a doctorate in biochemistry from a joint program at the University of California, Riverside, and UCLA.

My mother never even for one day let us think that females are different.

Jean Chen Shih, USC pharmacy professor

“My mother never even for one day let us think that females are different,” she said. “She believed education would bring us to a higher level to help more people.”

Her mother not only stressed academics, but also being a good person. She led by example: “When I was little and wanted to buy shoes, she would also buy shoes for the neighbor who was poorer than us.”

Shih believes she has continued her mother’s legacy of education and helping others through her teaching.

“I have been here 48 years, and my female students always write to me saying I serve as a role model for them and how much they appreciate me,” she said. “Some of their daughters have graduated from college now. I feel good that I have been able to pass along that important, good message.”

The post Pioneering pharmacy professor learned early to work hard and help others appeared first on USC News.

USC School of Pharmacy, Department of Biomedical Engineering announce naming gifts

USC and the Alfred E. Mann Foundation for Biomedical Engineering have launched a major initiative to reimagine biomedical engineering and pharmaceutical sciences for the 21st century. A gift from inventor and physicist Alfred E. Mann has grown to more than $230 million that will be used to support the expansion of USC’s academic and research activities at the intersection of health sciences and engineering.

To acknowledge this new focus and related investments, two USC entities will be renamed: USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the Alfred E. Mann Department of Biomedical Engineering within the USC Viterbi School of Engineering.

The USC Mann School of Pharmacy and Pharmaceutical Sciences will receive a $50 million endowment for student scholarships, faculty recruitment and integrating a universitywide research infrastructure related to biomedical innovation across USC’s University Park and Health Sciences campuses. It is the largest naming donation for a school of pharmacy in California.

The Mann Department of Biomedical Engineering will receive $35 million to expand medical engineering research, attract top faculty members and strengthen its ties with the Keck School of Medicine of USC. This is one of the largest naming gifts to a biomedical engineering department in the nation.

Additional funds will go toward interdisciplinary endowed chairs across multiple schools to support life-improving and life-saving research, innovation and student learning and the continued support of the Alfred E. Mann Institute for Biomedical Engineering at USC.

This sweeping initiative reflects Alfred Mann’s pioneering vision and has the power to expand human understanding in pharmaceutical sciences and biomedical engineering.

Carol L. Folt, USC president

“This sweeping initiative reflects Alfred Mann’s pioneering vision and has the power to expand human understanding in pharmaceutical sciences and biomedical engineering,” USC President Carol L. Folt said. “The Mann Foundation’s generosity will enhance USC’s academic research community and our ability to educate the next generation of providers and researchers, drive scientific innovation and create commercially successful medical products that improve public health.”

This initiative builds on Mann’s prescient work to develop and commercialize innovative solutions for the unmet medical needs of today and tomorrow.

“Al was a firm believer and dedicated his life’s work to the proposition that pharmacological science as well as biomedical engineering would both improve and extend the lives of millions if not billions of those afflicted,” three trustees of Alfred E. Mann’s charities and of the Alfred E. Mann Foundation for Biomedical Engineering — Michael Dreyer, Anoosheh Bostani and Claude Mann — said in a joint statement. “We wholeheartedly believe that associating Al’s name with the School of Pharmacy and the Department of Biomedical Engineering is a great way for his legacy to be remembered, as these were the fields he was most passionate about.”

With more than half of all pharmacists in Southern California trained at USC, the School of Pharmacy is moving beyond the traditional role of the field to position pharmacists as first-line medical staff and health care providers.

The endowment further enables the School of Pharmacy to continue its centurylong tradition of innovative programming, research, practice and collaboration. One of the first schools of pharmacy in the country at its founding in 1905, the school established itself as a trailblazer in changing the education, requirements and professional career path of pharmacy early on by training professionals across the continuum of pharmaceutical sciences, from clinical care to economics.

With 117 years under its belt, the school is one of the top pharmacy schools nationwide and the highest-ranked private pharmacy school. USC was the first school in the nation to offer a Doctor of Pharmacy degree, as well as a clinical pharmacy program, clinical clerkships, doctorates in pharmaceutical economics and regulatory science, and a PharmD/MBA dual-degree program, among other innovations in education, research and practice.

“Our fields are ever-evolving, and as health care needs change, this $50 million endowment will give us the flexibility and wherewithal to quickly pursue bold ideas and innovations that anticipate and are ahead of the curve in meeting those changes,” said Vassilios Papadopoulos, dean of the USC Mann School of Pharmacy and Pharmaceutical Sciences. “We will have the agility, coupled with the know-how and determination, to address new opportunities and challenges as they arise, recruit and retain top interdisciplinary faculty, and increase the aid we are able to offer to attract the best and brightest students from across the country and around the world.

“The naming really makes perfect sense, because Alfred E. Mann was also a person who believed in the business of pharmacy,” Papadopoulos said. “It is not only knowledge; health care also has a business and economics aspect. When I was told about the interest, I thought this would definitely be fitting for everything the School of Pharmacy does, from discovery to application.”

Throughout his long and distinguished career, Mann founded companies and funded the creation of products that revolutionized the health care field. He also donated more than $174 million to USC toward advancements for human health, including the establishment of AMI-USC, which has been instrumental in creating groundbreaking medical inventions such as the artificial retina. Mann, who died in 2016, was a member of the university’s Board of Trustees and also served on the Board of Overseers of Keck School of Medicine of USC.

Quick action during the pandemic inspires naming gift

Students and faculty from the School of Pharmacy drew national attention during the pandemic for their work vaccinating hundreds of thousands of community members. The pandemic revealed how essential pharmacists are within a traditional health care team.

“This is one of the few positive things of the pandemic,” Papadopoulos said. “This is where people realized that primary care can be done by pharmacists and that the pharmacy really is the place where people connect with their health care provider.”

Richard Dang, assistant professor of clinical pharmacy and residency program director at the School of Pharmacy, agrees: “Many members of government and the community recognized that pharmacists can play a major role in the delivery of health care, and it’s beyond the traditional image of simply providing a medication. It’s also opened the eyes of our own students and staff to the magnitude of impact that they can have as a pharmacist.”

When multiple COVID-19 vaccines gained FDA approval near the end of 2020, the School of Pharmacy sprang into action, partnering with key Los Angeles entities, including the mayor’s office, L.A. Fire Department and the nonprofit Community Organized Relief Effort, to ensure that vaccines were available where Angelenos work, live and play.

This swift action is part of the inspiration for the school’s new naming gift. The permanent endowment represents a vote of confidence in the quality of the school and a guarantee that it remains a top-tier destination for the world’s best in pharmaceutical sciences and research.

Only about a quarter of pharmacy schools around the country have been named. Around the nation, the endowment is believed to be second in size only to the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill.

“This endowment will allow the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences to extend its commitment to health equity, wellness and best possible patient outcomes,” said Steven D. Shapiro, senior vice president for health affairs at USC. “We look forward to new opportunities for innovative discoveries as we train the next generation of health care leaders, expand interdisciplinary collaborations within the university and improve the health of our local Los Angeles community.”

Department of Biomedical Engineering bridges the gap between engineering and medicine

For USC Viterbi Dean Yannis C. Yortsos, the Department of Biomedical Engineering’s naming gift is a natural offshoot of the department’s early and close affiliation with AMI. Yortsos hopes to use some of the funds to expand the department’s programming and research and deepen its relationship with Keck School of Medicine of USC.

“The fundamental idea is that technology enables all aspects of health sciences — whether in neuroscience, molecular biology, diagnostics, synthetic biology, devices or pharmaceuticals — as well as the practice of medicine, to advance the well-being and health of all,” Yortsos said. “The strong set of health sciences schools at USC and USC Viterbi are natural and strong partners in the advancement of this initiative.”

Yortsos pointed out that many faculty members in USC Viterbi — even outside of biomedical engineering — have joint appointments or projects with applications in biology and medicine, a fact he believes highlights the breadth and scope of the department. He pointed to the work of USC Professor of Ophthalmology and Biomedical Engineering Mark Humayun as an example of how engineering and medicine can go hand-in-hand to achieve Mann’s vision of life-improving medical technologies that can be commercialized. Humayun, director of the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics, is both an ophthalmologist and biomedical engineer who led a diverse team to develop the world’s first artificial retina, approved by the Food and Drug Administration in 2013. The project was backed by AMI and an example of the strong connection between the institute and the Department of Biomedical Engineering.

Likewise, in 2011, a brain implant developed by the biomedical engineering lab of USC Viterbi Professor Ted Berger became the first medical device in the world to restore lost memory function and strengthen the recall of memories. The MIT Technology Review later named it as one of the Breakthrough Technologies of 2013.

And since 1985, the USC Biomedical Simulations Resource, USC Viterbi’s longest continuously funded National Institutes of Health research center led by Viterbi professors Vasilis Marmarelis and David D’Argenio, has produced software like ADAPT, used in the development of Herceptin, which is the first biologic developed for the treatment of breast cancer, as well as Rituxan for treating non-Hodgkin lymphoma.

The department, established in 1976, is one of the oldest biomedical engineering departments in the country, born from advances in electrical and mechanical engineering and the realization that engineering innovation could be beneficial to the human body. It is the first such program in California to offer bachelor, master and doctoral degrees. An early pioneer in neural engineering, medical devices, diagnostics and, more recently, in molecular bioengineering, the department has achieved many notable successes.

“Technology is revolutionizing medicine and health sciences in an unprecedented way with the goal of living without illness,” Yortsos said. “Biomedical engineering will play a fundamental role in that objective for the benefit of humanity.”

Looking forward

Papadopoulos says his hope for the newly named USC Mann School of Pharmacy and Pharmaceutical Sciences is to train students to address the issues and pandemics of tomorrow, “possibly through jobs that don’t even exist yet.” One current problem affecting the Los Angeles community is pharmacy deserts, an issue Dima M. Qato, community pharmacist, public health advocate and associate professor at the School of Pharmacy, has spent more than a decade addressing.

To help meet that need, the school plans to open a new USC pharmacy on the corner of Manchester Avenue and Broadway in South Los Angeles late next year that will go beyond filling prescriptions. The facility will also offer chronic disease management, vaccinations, health and wellness education for the community, and research on best practices and health policies to reduce health disparities.

For Yortsos, the naming gift likewise opens new doors for the kind of talent and innovation the Department of Biomedical Engineering will need to create the medical and technological solutions of tomorrow. “Naming the department has always been an important goal of the school since it provides additional resources for growth and global impact,” Yortsos said. “It is also a testament to the university’s commitment to advancing the field.”

The post USC School of Pharmacy, Department of Biomedical Engineering announce naming gifts appeared first on USC News.

New drug shows promise for fighting both COVID-19 and cancer

REDIRECT 8011
https://keck.usc.edu/new-drug-shows-promise-for-fighting-both-covid-19-and-cancer/
Story Headline and Deck – USC News *
New drug shows promise for fighting both COVID-19 and cancer

Researchers at the Keck School of Medicine of USC and the Cleveland Clinic Florida Research and Innovation Center have published new studies of GRP78, a protein implicated in both COVID-19 and multiple types of cancer, and a new drug that interferes with its effects.
Body Copy *

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot get vaccinated or in the event that dangerous new strains of the virus arise that could bypass vaccine protection.

Now, a new study from a team of researchers led by Amy S. Lee, PhD, professor of biochemistry and molecular medicine at the Keck School of Medicine of USC, shows that a chaperone protein known as GRP78, implicated in the spread of other viruses, plays an essential role in the spread of SARS-CoV-2, the virus that causes COVID-19. The study also shows that blocking the production of GRP78, or inhibiting its activity with a new targeted drug, greatly reduced the replication of SARS-CoV-2.

The research, just published in the journal Nature Communications, suggests this drug could potentially offer a new type of protection against COVID-19, one that might remain effective even as new strains develop.

“A major problem in fighting SARS-CoV-2 is that it is constantly mutating and adapting itself to more efficiently infect and multiply in its host cells,” said Lee, also the Judy and Larry Freeman Chair in basic science research. “If we keep chasing the virus around, this could become quite challenging and unpredictable.”

GRP78’s role in the spread of viruses

Searching for a more stable way to combat COVID-19, Lee and her colleagues at the Keck School of Medicine of USC and the Cleveland Clinic Florida Research and Innovation Center began exploring the role of GRP78, a key cellular chaperone protein that helps regulate the folding of other cellular proteins. While healthy cells need a fraction of GRP78 to function normally, cells under stress need more GRP78 to cope. The Keck School of Medicine researchers showed in a 2021 paper that when SARS-CoV-2 enters the scene, GRP78 is hijacked to work in tandem with other cellular receptors to bring the SARS-CoV-2 virus inside cells, where it can then reproduce and spread.

But questions remained about whether GRP78 is “necessary and essential” for SARS-CoV-2 replication inside human lung cells. Examining human lung epithelial cells infected with SARS-CoV-2, the research team observed that as the viral infection intensifies, the infected cells produce higher levels of GRP78.

The power of inhibiting GRP78

Then Lee and her team used a special messenger RNA tool to suppress production of the GRP78 protein in human lung epithelial cells in cell culture, without interrupting other cellular processes. When those cells were later infected with SARS-CoV-2, they produced a lower amount of the viral spike protein and released much less of the virus to infect other cells, proving that GRP78 was necessary and essential for viral replication and production.

“We now have direct evidence that GRP78 is a proviral protein that is essential for the virus to replicate,” Lee said.

To further explore whether targeting GRP78 could work to treat COVID-19, the researchers tested a recently identified small molecule drug, known as HA15 on the infected lung cells. This drug, developed for use against cancer cells, specifically binds GRP78 and inhibits its activity.

“Lo and behold, we found that this drug was very effective in reducing the number and size of SARS-CoV-2 plaques produced in the infected cells, in safe doses which had no harmful effect on normal cells,” Lee said.

The researchers then tested HA15 in the body of mice that were genetically engineered to express a human SARS-CoV-2 receptor and infected with SARS-CoV-2, finding that the drug greatly reduced viral load in the lungs.

Drugs that target GRP78

Separately, Lee and her colleagues at the Keck School of Medicine are studying the efficacy of HA15 in cancer, as well as another GRP78 inhibitor, YUM70, in collaboration with researchers at the University of Michigan. They discovered that HA15 and YUM70 can suppress the production of mutant KRAS proteins–a common mutation that tends to resist drug treatment–and reduce the viability of cancer cells bearing such mutations in pancreatic, lung and colon cancer. Those findings, just published in the journal Neoplasia, suggest targeting GRP78 may help combat these deadly cancers.

These are basic proof of principle studies; further research, including clinical trials, is needed to establish that HA15 and YUM70 are safe and effective for use in humans. These and other GRP78 inhibitors are now being tested as treatments for both COVID-19 and cancer. These drugs may also prove useful for treating future coronaviruses that depend on GRP78 for entry and replication, Lee said.

About this study

In addition to Lee, the Nature Communications study’s other authors are Dat Ha of the Department of Biochemistry & Molecular Medicine, Keck School of Medicine of USC; Keigo Machida of the Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC; and Woo-Jin Shin of the Florida Research and Innovation Center, Cleveland Clinic.

This research is facilitated by USC’s Biosafety-Level 3 containment laboratory, allowing the team to safely study the SARS-CoV-2 infection in genetically engineered mice.

The study was supported by the National Institutes of Health [R01 CA238029, R01 CA027607, R01 AA025204-01A1], a pilot grant from a gift by the W. M. Keck Foundation to support COVID-19 research and the Korea Research Institute of Bioscience and Biotechnology [KGM9942011].

The post New drug shows promise for fighting both COVID-19 and cancer appeared first on USC News.

Keck Hospital of USC nationally recognized with 7th consecutive ‘A’ hospital safety grade

For the seventh consecutive time, Keck Hospital of USC earned an “A” Hospital Safety Grade from The Leapfrog Group, an independent national watchdog organization, for achieving the highest national standards in patient safety.

“Keck Medicine is dedicated to providing quality care, and we are proud once again to be recognized as one of the safest hospitals in the nation,” said Marty Sargeant, CEO of Keck Hospital and USC Norris Cancer Hospital.

The Leapfrog Group assigns letter grades to general hospitals throughout the United States based on a hospital’s ability to prevent medical errors and harm to patients. Hospital Safety Grade results are based on more than 30 national performance measures and are updated each fall and spring.

“While Keck Hospital has received an ‘A’ grade since 2019, we’re honored to share that this year, we received the highest score on performance measurements we’ve ever achieved,” said Stephanie Hall, chief medical officer of Keck Hospital and USC Norris Cancer Hospital. “This distinction reflects the commitment of the entire staff to the highest standards of care as we continue to ensure a safe environment patients can trust.”

The Leapfrog Group grading system is peer-reviewed, fully transparent and free to the public. See Keck Hospital’s full grade details and access hospital safety tips for patients online.

The post Keck Hospital of USC nationally recognized with 7th consecutive ‘A’ hospital safety grade appeared first on USC News.